Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
Year: 2022
Type: review
Abstract: Several randomized controlled trials have demonstrated the benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in patients with diabetes. In this review, we summarize and discuss the potential mechanisms of stroke protection by GLP-1RAs. GLP-1RAs exert multiple anti-atherosclerotic effects contributing to stroke prevention such as enhanced plaque stability, reduced vascular smooth muscle proliferation, increased nitric oxide, and improved endothelial function. GLP-1RAs also lower the risk of stroke by reducing traditional stroke risk factors including hyperglycemia, hypertension, and dyslipidemia. Independently of these peripheral actions, GLP-1RAs show direct cerebral effects in animal stroke models, such as reduction of infarct volume, apoptosis, oxidative stress, neuroinflammation, excitotoxicity, blood-brain barrier permeability, and increased neurogenesis, neuroplasticity, angiogenesis, and brain perfusion. Despite these encouraging findings, further research is still needed to understand more thoroughly the mechanisms by which GLP-1RAs may mediate stroke protection specifically in the human diabetic brain.
Source: Cardiovascular Diabetology
Institutions: Inserm, Université de Bourgogne, CHU Dijon Bourgogne, Centre de recherche Translationnelle en Médecine moléculaire, Centre Hospitalier Universitaire de Limoges, Hôpital Universitaire Dupuytren, Institut de Recherche pour le Développement, Épidémiologie des maladies chroniques en zone tropicale, Université de Limoges, Université de Tours, Centre Hospitalier Universitaire de Tours, Université Paris Cité, Hôpital Européen Georges-Pompidou, Paris Cardiovascular Research Center, Centre National de la Recherche Scientifique, Institut du Thorax, Nantes Université, Assistance Publique – Hôpitaux de Paris, Université de Bordeaux, Biologie des maladies cardiovasculaires, Hôpital Bichat-Claude-Bernard
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: GLP-1 receptor agonists, ischemic stroke, stroke prevention, diabetes mellitus, anti-atherosclerotic effects, plaque stability, endothelial function, nitric oxide, vascular smooth muscle cell proliferation, hyperglycemia, hypertension, dyslipidemia, cerebral effects, infarct size, neuroinflammation, oxidative stress, blood-brain barrier permeability, neurogenesis, neuroplasticity, angiogenesis, cerebral perfusion
Open Access status: gold
Estimated APC paid: $3,590
Funder: Novo Nordisk
OpenAlex ID: W4309438512
